<DOC>
	<DOCNO>NCT00515723</DOCNO>
	<brief_summary>Hyperglycemia type 2 diabetes mellitus common schizophrenia general population . Type 2 diabetes mellitus characterize disturbance insulin action skeletal muscle , liver adipose tissue . Diabetes cause increase morbidity mortality due acute ( e.g. , diabetic ketoacidosis ) long-term ( e.g. , cardiovascular disease ) complication . The combination hyperglycemia , dyslipidemia abdominal adiposity even strongly associate increase cardiovascular morbidity mortality . The association type 2 diabetes hyperglycemia schizophrenia first note prior introduction antipsychotic medication , suggest patient may increase risk . Since , however , additional glucoregulatory abnormality ( e.g. , new onset diabetes ) , dyslipidemia , increase weight adiposity associate antipsychotic medication . Concern antipsychotic effect glucose , lipids adiposity increase recently , focus widely-used newer medication , clozapine olanzapine . Increased abdominal adiposity secondarily decrease insulin sensitivity antipsychotic increase adiposity . However , medication effect glucose control insulin action may also occur independent difference adiposity . This project aim ) evaluate effect select antipsychotic medication insulin action skeletal muscle ( glucose disposal ) , liver ( glucose production ) adipose tissue ( whole-body lipolysis ) , b ) evaluate effect select antipsychotic medication abdominal adipose tissue mass , total body fat total fat-free mass , c ) explore longitudinal effect treatment select antipsychotic glucose tolerance , lipid profile , abdominal adipose tissue mass , total body fat total fat-free mass . These hypothesis evaluate measure 1 ) whole-body glucose lipid kinetics use `` gold-standard '' stable isotope tracer methodology , 2 ) body composition use dual energy x-ray absorptiometry magnetic resonance imaging , 3 ) longitudinal change glucose tolerance lipid profile . The aim address non-diabetic schizophrenia patient chronically treat risperidone , olanzapine , clozapine , quetiapine , ziprasidone , haloperidol , untreated healthy control . Re-evaluations also perform patient randomize switch current antipsychotic ( group ) risperidone , olanzapine , quetiapine , ziprasidone 6 month . Relevant data critically need target basic research , identify long-term cardiovascular consequence , plan therapeutic intervention .</brief_summary>
	<brief_title>Glucose Lipid Metabolism Antipsychotic Medication</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Aged 1860 year Patients : otherwise healthy meet DSMIV criterion schizophrenia schizoaffective disorder , type , treat haloperidol , olanzapine , clozapine , quetiapine , ziprasidone , aripiprazole , risperidone least 3 month Controls : healthy Able give inform consent No antipsychotic medication change 3 month , medication change 2 week prior Baseline Evaluations . Axis I psychiatric disorder criterion meet self except substance use disorder Patients control : meet DSMIV criterion diagnose substance abuse within past 3 month Involuntary legal status ( per Missouri law ) The presence serious medical disorder may confound assessment relevant biologic measure diagnosis , include : significant organ system dysfunction , metabolic disease , type 1 diabetes mellitus , symptomatic type 2 diabetes mellitus ( see ) , pregnancy , endocrine disease , coagulopathy , clinically significant anemia , would preclude blood sampling ( determined PI ) acute infection ; Patients take one atypical antipsychotic medication ; Subjects take certain prescription medication ( determine PI case case basis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>control</keyword>
	<keyword>risperidone</keyword>
	<keyword>olanzapine</keyword>
	<keyword>quetiapine</keyword>
	<keyword>ziprasidone</keyword>
</DOC>